Logo image of YMTX

YUMANITY THERAPEUTICS INC (YMTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:YMTX - US98872L1026 - Common Stock

1.89 USD
+0.15 (+8.62%)
Last: 12/16/2022, 8:00:02 PM
1.9 USD
+0.01 (+0.53%)
After Hours: 12/16/2022, 8:00:02 PM
Fundamental Rating

1

Overall YMTX gets a fundamental rating of 1 out of 10. We evaluated YMTX against 528 industry peers in the Biotechnology industry. While YMTX seems to be doing ok healthwise, there are quite some concerns on its profitability. YMTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • YMTX had negative earnings in the past year.
  • YMTX had a negative operating cash flow in the past year.
YMTX Yearly Net Income VS EBIT VS OCF VS FCFYMTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M

1.2 Ratios

  • The profitability ratios for YMTX are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
YMTX Yearly ROA, ROE, ROICYMTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for YMTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
YMTX Yearly Profit, Operating, Gross MarginsYMTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

  • YMTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, YMTX has more shares outstanding
  • The debt/assets ratio for YMTX is higher compared to a year ago.
YMTX Yearly Shares OutstandingYMTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
YMTX Yearly Total Debt VS Total AssetsYMTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -35.79, we must say that YMTX is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -35.79, YMTX is doing worse than 94.38% of the companies in the same industry.
  • There is no outstanding debt for YMTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -35.79
ROIC/WACCN/A
WACC9.55%
YMTX Yearly LT Debt VS Equity VS FCFYMTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 2.21 indicates that YMTX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.21, YMTX is doing worse than 80.97% of the companies in the same industry.
  • A Quick Ratio of 2.21 indicates that YMTX has no problem at all paying its short term obligations.
  • YMTX has a worse Quick ratio (2.21) than 79.25% of its industry peers.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 2.21
YMTX Yearly Current Assets VS Current LiabilitesYMTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

  • YMTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -337.84%.
  • The Revenue for YMTX has decreased by -65.84% in the past year. This is quite bad
  • Measured over the past years, YMTX shows a decrease in Revenue. The Revenue has been decreasing by -0.82% on average per year.
EPS 1Y (TTM)-337.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.04%
Revenue 1Y (TTM)-65.84%
Revenue growth 3Y41.49%
Revenue growth 5Y-0.82%
Sales Q2Q%-14.25%

3.2 Future

  • Based on estimates for the next years, YMTX will show a small growth in Earnings Per Share. The EPS will grow by 4.21% on average per year.
  • The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-60.56%
EPS Next 2Y-59.53%
EPS Next 3Y-27.59%
EPS Next 5Y4.21%
Revenue Next Year9.96%
Revenue Next 2Y14.87%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
YMTX Yearly Revenue VS EstimatesYMTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
YMTX Yearly EPS VS EstimatesYMTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • YMTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year YMTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YMTX Price Earnings VS Forward Price EarningsYMTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YMTX Per share dataYMTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

  • YMTX's earnings are expected to decrease with -27.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-59.53%
EPS Next 3Y-27.59%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for YMTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

YUMANITY THERAPEUTICS INC

NASDAQ:YMTX (12/16/2022, 8:00:02 PM)

After market: 1.9 +0.01 (+0.53%)

1.89

+0.15 (+8.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)03-22
Inst Owners0%
Inst Owner Change0%
Ins Owners7.84%
Ins Owner Change0%
Market Cap20.52M
Revenue(TTM)4.84M
Net Income(TTM)-32.00M
Analysts84.44
Price Target35.7 (1788.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.65%
Min EPS beat(2)55.44%
Max EPS beat(2)71.86%
EPS beat(4)4
Avg EPS beat(4)35.85%
Min EPS beat(4)6.92%
Max EPS beat(4)71.86%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-40.02%
Min Revenue beat(2)-45.02%
Max Revenue beat(2)-35.02%
Revenue beat(4)0
Avg Revenue beat(4)-47.13%
Min Revenue beat(4)-58.63%
Max Revenue beat(4)-35.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-45.33%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.24
P/FCF N/A
P/OCF N/A
P/B 3.75
P/tB 3.75
EV/EBITDA N/A
EPS(TTM)-2.64
EYN/A
EPS(NY)-9.8
Fwd EYN/A
FCF(TTM)-2.36
FCFYN/A
OCF(TTM)-2.35
OCFYN/A
SpS0.45
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 2.21
Altman-Z -35.79
F-Score3
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)18.35%
Cap/Depr(5y)17.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-337.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.04%
EPS Next Y-60.56%
EPS Next 2Y-59.53%
EPS Next 3Y-27.59%
EPS Next 5Y4.21%
Revenue 1Y (TTM)-65.84%
Revenue growth 3Y41.49%
Revenue growth 5Y-0.82%
Sales Q2Q%-14.25%
Revenue Next Year9.96%
Revenue Next 2Y14.87%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y52.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.46%
OCF growth 3YN/A
OCF growth 5YN/A

YUMANITY THERAPEUTICS INC / YMTX FAQ

What is the fundamental rating for YMTX stock?

ChartMill assigns a fundamental rating of 1 / 10 to YMTX.


What is the valuation status for YMTX stock?

ChartMill assigns a valuation rating of 1 / 10 to YUMANITY THERAPEUTICS INC (YMTX). This can be considered as Overvalued.


Can you provide the profitability details for YUMANITY THERAPEUTICS INC?

YUMANITY THERAPEUTICS INC (YMTX) has a profitability rating of 1 / 10.


What is the expected EPS growth for YUMANITY THERAPEUTICS INC (YMTX) stock?

The Earnings per Share (EPS) of YUMANITY THERAPEUTICS INC (YMTX) is expected to decline by -60.56% in the next year.